R&D
Moderna Revamps R&D Strategy with $1.1B Cuts and Pipeline Overhaul
Moderna, R&D cuts, pipeline overhaul, biotechnology, pharmaceutical industry, cost reduction, research and development.
Repare Therapeutics Cuts 25% of Workforce, Preclinical Team Most Affected
Repare Therapeutics, layoffs, preclinical team, R&D prioritization, biotech industry
Aadi Bioscience Cuts 80% of R&D Staff Amid Fyarro Expansion Setbacks
Aadi Bioscience, R&D workforce, Fyarro, expansion efforts, layoffs, pharmaceutical industry
BioMarin Appoints New R&D and Business Development Leaders
BioMarin, R&D, Business Development, Leadership, Greg Friberg, James Sabry, Hank Fuchs
Genentech Closes Cancer Immunology Unit as Part of Broader R&D Restructuring
Genentech, Cancer Immunology, R&D Reprioritization, Roche, Cancer Research, Molecular Oncology
Incyte Discontinues Five Early-Stage Oncology Programs in Pipeline Refocus
Incyte, cancer pipeline, oncology programs, PD-L1 inhibitors, strategic review, R&D refocus
Pfizer Faces Key R&D Challenges as Chief Scientific Officer Mikael Dolsten Departs
Pfizer, Mikael Dolsten, Chief Scientific Officer, R&D Challenges, Biopharma Industry
Gilead’s Antibody Finds New Life with $40M Investment in Small Biotech
Gilead, antibody, small biotech, $40M investment, oncology R&D
Revolutionizing Research and Development: Xaira Unveils AI-Driven Platform with $1B Funding and Former Genentech Leaders
AI-Powered Xaira, $1B funding, Genentech executives, R&D transformation, biotechnology innovation, artificial intelligence in research, life sciences advancement.
Ipsen and Skyhawk Therapeutics Join Forces in a $1.8 Billion Deal to Advance RNA Modulator Research
Ipsen, Skyhawk Therapeutics, RNA modulators, drug discovery, partnership, $1.8 billion, biopharmaceutical, R&D, therapeutic development